Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Additional Phase II Data Demonstrate Improvement In Reported Symptoms In Patients Who Still Experience GERD Symptoms Despite PPI Therapy
Adding AZD3355, a novel GABAB receptor agonist, to a proton pump inhibitor (PPI) in patients with Gastroesophageal Reflux Disease (GERD), resulted in a 35% reduction in the mean total number of reflux episodes 0-24 hours after dose, compared with placebo.[i] These data were presented at the Digestive Diseases Week annual meeting (DDW®, 30 May - 4 June, Chicago).
generic viagra online
64% Of Total Polyps Detected By Conventional Colonoscopy Are Diagnosed By Minimally Invasive Colon Capsule Endoscopy
Capsule endoscopy for exploring the colon in a minimally invasive manner diagnoses 64% of all lesions located by means of conventional colonoscopy. According to a study published in The New England Journal of Medicine - the specialised medical journal with greatest international impact -, the new device would need technical improvements to achieve similar efficacy to the conventional procedure undertaken with a colonoscopy and to date considered a "gold standard" technique for this medical discipline, given that this is what currently provides the most reliable results. It has to be added that, moreover, conventional colonoscopy enables the undertaking of a diagnosis of the colon as well as practicing therapeutic procedures, such as the in situ extirpation of polyps during exploration or the obtaining of a biopsy when required.
News of the day
Better Classification And Treatment Of Juvenile Arthritis Via Gene Expression
Scientists have discovered gene expression differences that could lead to better ways to classify, predict outcome, and treat juvenile idiopathic arthritis (JIA). Eventually such findings could enable doctors to target more aggressive treatment to children at risk of more severe arthritis, while those likely to have milder disease could be spared the stronger treatments that carry a greater risk of side effects. The researchers were supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health.
Endocrinology

Watson Pharmaceuticals Receives A Complete Response Letter For Its 24-Week Formulation Of TRELSTAR(R) (triptorelin Pamoate) NDA From US FDA

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for TRELSTAR(R) 22.5 mg (triptorelin pamoate for injectable suspension), a 24-week formulation of TRELSTAR(R) for the palliative treatment of advanced prostate cancer. The TRELSTAR(R) NDA was prepared in cooperation with Debiopharm Group, a Swiss-based global biopharmaceutical group of companies. According to the letter, the FDA has requested clarifications related to the clinical testing of the product, additional information regarding the chemistry, manufacturing and controls (CMC) of the product and other components, and information related to third party manufacturing. Watson is working to ensure the requested information is provided to the FDA expeditiously. TRELSTAR(R) 22.5 mg builds on Watson"s long-standing track record in prostate cancer and expanding urology franchise. The new, longer-acting formulation of TRELSTAR(R) is designed to be conveniently administered and to continuously suppress the production of testosterone in men with advanced prostate cancer for 24 weeks. TRELSTAR(R) is an already proven therapy with established efficacy and safety in two formulations - a four-week formulation (TRELSTAR(R) DEPOT) and a 12-week formulation (TRELSTAR(R) LA). About TRELSTAR(R) TRELSTAR(R), developed by Debiopharm Group and marketed by Watson, administers a synthetic luteinizing hormone releasing hormone (LHRH) agonist, triptorelin, which suppresses the production of testosterone in the testicles. Prostatic cancer proliferation is regulated in part by the level and activity of testosterone. TRELSTAR(R) is currently available in a four-week depot formulation (TRELSTAR(R) DEPOT) and a 12-week long-acting formulation (TRELSTAR(R) LA), offering an alternative treatment for prostate cancer when orchiectomy (removal of the testicles) or estrogen administration are either not indicated or unacceptable to the patient. TRELSTAR(R) does not require refrigeration and should be stored at controlled room temperature. Important Safety Information In clinical trials, the most common adverse events occurring in patients were hot flushes, skeletal pain, impotence and headache. As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels and may initiate or worsen symptoms during this transient period. Rare post-marketing reports of anaphylactic shock and angioedema have been reported. TRELSTAR(R) is contraindicated for use in women. About Watson Pharmaceuticals, Inc. Watson Pharmaceuticals, Inc., is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women"s Health and Nephrology/Medical. About Debiopharm Group Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs. Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales of $2.6 billion in 2008. Forward-Looking Statement Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson"s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson"s current expectations depending upon a number of factors affecting Watson"s business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson"s products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson"s periodic public filings with the Securities and Exchange Commission, including but not limited to Watson"s Annual Report on Form 10-K for the year ended December 31, 2008. Watson Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009